Bartronics India Ltd

Collaboration overview

• ASMS and Huwel Lifesciences will build a nationwide commercialisation platform for Cubo RT-PCR.
• The initiative will expand molecular diagnostics access in private hospitals, labs, and clinics.

Execution plan

• Dedicated sales and distribution infrastructure will be established.
• Senior sales leadership recruitment and specialised teams will be formed.
• Strategic channel partnerships will be developed to broaden market coverage.
• Initial focus on Cubo with expansion to Huwel's broader portfolio.
• Target private hospitals, diagnostic chains, independent labs, and research institutions.

Avio Smart Market Stack Limited closes trading window from 01 October 2026 till 48 hours after the declaration of un-audited financial results for quarter and half year ending September 30, 2026

Purpose and revisions

• Corrigendum to AGM notice issued Sept 25, 2026.
• Total equity shares for preferential issue revised to 11,13,02,372.
• Issue price revised to ₹7.73 per share (premium ₹6.73).
• Aggregate issue amount revised to ₹85,98,99,866.
• 66,212 Ampivo shares transfer unchanged.

Ownership, approvals and pricing

• Identity and post-issue holdings of proposed allottees revised.
• Price determined as higher of NSE 90-day VWAP; revised to ₹7.73.
• Valuation updated; fair value set at ₹7.73 per share; other methods lower.
• Relevant date remains 31 August 2026; approvals addressed via corrigendum.
• Promoter holding post-issue 48.21%; public holding 51.79%.

Key Update

• XBRL-PDF discrepancy due to mapping error in XBRL taxonomy.
• Finance Costs shown as Nil in XBRL; ₹27.42 Lakhs should be included.
• XBRL PBT overstated at ₹150.17 Lakhs; correct PBT is ₹122.75 Lakhs.
• Annexure A figures remain the same as approved by the Board on August 12, 2026.
• Company will re-submit corrected XBRL filing aligning with Annexure A.

Financial results

• Board approved the Board's Report for FY ended 31 March 2026, with annexures.

Auditor appointment

• Board recommended M/s SVRL & Co. as statutory auditors for five years, subject to member approval.

Fundraising via QIP

• Board approved QIP up to ₹150 crore, subject to member approvals and regulatory clearances.

Ampivo acquisition

• Acquisition of 43.44% Ampivo via share-swap; up to 11,02,42,980 shares at ₹7.80 each.
• Valuation report by Ms. R. Abinaya submitted for Ampivo transaction.
• Share Purchase and Subscription Agreement with Ampivo executed.

AGM planning

• Cut-off date for remote e-voting fixed 23 Sep 2026.
• AGM scheduled 30 Sep 2026 via VC/OAVM.
• Remote voting window 27-29 Sep 2026.
• NSDL appointed for e-voting; Scrutinizer Shaik Ibraheem appointed.

Meeting Details

• Meeting date: September 03, 2026; time and venue not disclosed.

Key Agenda Items

• Draft Board's Report for year ended March 31, 2026 to be considered.
• Recommend SVRL & Co. as Statutory Auditors, subject to approvals.
• Propose fund-raising via Equity Shares through a QIP.
• Consider further acquisition of equity in Ampivo Smart Technologies Private Limited.
• Approve preferential issue of Equity Shares under applicable provisions.
• Set AGM date/time/venue and approve the AGM Notice.
• Approve closure of Register of Members and Share Transfer Books for AGM.
• Appoint e-voting agency and Scrutinizer for AGM voting.

Other Notes

• Trading window closed for Designated Persons from Sep 1, 2026 until 48 hours after public disclosure.

Step-down subsidiary incorporation

• Incorporation of AVIO Healthcare Corporation in the Philippines as a step-down subsidiary of BIL Healthtech.
• BIL Healthtech holds 69.99% of AVIO Healthcare Corporation.
• Total subscription commitment: PHP 2,274,700.
• Subscribed 22,747 shares, 69.99% of AVIO Healthcare's capital.
• Date of incorporation: August 12, 2026.
• Country of incorporation: Republic of the Philippines.
• Business scope includes import/export of medical products; AVIO Healthcare has 99.993% foreign equity.
• Investment subject to foreign exchange and overseas investment regulations.
• AVIO Healthcare becomes related party to BIL Healthtech and Avio.
• Subscription amount not yet remitted by BIL Healthtech.

Financial results approved

• Standalone unaudited results for quarter ended 30 June 2026 approved.
• Consolidated unaudited results for quarter ended 30 June 2026 approved.

MD appointment

• MD N. Vidhya Sagar Reddy re-appointed for 3 years from Aug 12, 2026, subject to shareholders' approval.

Regulatory and governance

• Trading window remains closed; reopens 48 hours after results are published.
• Emphasis of Matter: impairment under Resolution Plan; RBI approvals for write-backs may be required.
• Singapore branch results included; not reviewed by auditors.
• Tax assessments for AY 2019-20 and 2020-21 pending; related balances retained.

Investments and subsidiaries

• Acquired 25.76% stake in Shree Naganarasimha Private Limited on 06 Mar 2026.
• Additional 15.20% stake acquired on 08 Apr 2026; total 40.96% as of 30 Jun 2026.
• Formed two wholly owned subsidiaries: BIL AgriTech Private Limited and BIL HealthTech Private Limited.

Auditor remarks

• Independent auditor's review notes impairment and RBI approval requirements; no modification to conclusions.